key: cord-0715455-uuzdy9f6
authors: Cappel, Mark A.; Cappel, Jonathan A.; Wetter, David A.
title: Pernio (Chilblains), SARS-CoV-2, and COVID Toes Unified Through Cutaneous and Systemic Mechanisms
date: 2021-01-21
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2021.01.009
sha: 63291fc795abcd87aa66d690894e197435e90669
doc_id: 715455
cord_uid: uuzdy9f6

Pernio or chilblains is characterized by erythema and swelling at acral sites (eg, toes and fingers), typically triggered by cold exposure. Clinical and histopathologic features of pernio are well described, but the pathogenesis is not entirely understood; vasospasm and a type I interferon (IFN-I) immune response are likely involved. During the coronavirus disease 2019 (COVID-19) pandemic, dermatologists have observed an increase in pernio-like acral eruptions. Direct causality of pernio due to COVID-19 has not been established in many cases because of inconsistent testing methods (often negative results) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, a form of COVID-19‒associated pernio (also called COVID toes) is likely because of the increased occurrence, frequently in young patients with no cold exposure or prior history of pernio, and reports of skin biopsies with positive SARS-CoV-2 immunohistochemistry. PubMed was searched for 2020 publications using the following keywords: pernio, chilblain, and acral COVID-19. On the basis of our review of the published literature, we speculate that several unifying cutaneous and systemic mechanisms may explain COVID-19‒associated pernio: 1) SARS-CoV-2 cell infection occurs through the cellular receptor angiotensin-converting enzyme 2 (ACE2) mediated by transmembrane protease serine 2 (TMPRSS2), subsequently affecting the renin-angiotensin-aldosterone system (RAAS) with an increase in the vasoconstricting, proinflammatory, and prothrombotic angiotensin II pathway. 2) SARS-CoV-2 cell infection triggers an immune response with robust IFN-I release in patients predisposed to COVID-19‒associated pernio. 3) Age and sex discrepancies correlated with COVID-19 severity and manifestations, including pernio as a sign of mild disease, are likely explained by age-related immune and vascular differences influenced by sex hormones and genetics, which affect susceptibility to viral cellular infection, the RAAS balance, and the IFN-I response.

Pernio or chilblains is a well-described cold-induced dermatosis, characterized by erythema and swelling localized to acral areas, occurring most commonly on the toes and fingers (Figures 1 and 2 1 ). Etymologic origins for these terms are from Latin (perna [leg]), Greek (-osis [abnormal condition]), and English (chil [cold] and blain [skin swelling]). 2 Proposed diagnostic criteria include required major criteria (localized erythema and swelling involving acral sites and persistence for >24 hours) and at least 1 of the following minor criteria: onset or worsening in cooler months, consistent histopathology, and response to conservative warming treatments. 3 Various laboratory abnormalities, including cold agglutinins and antiphospholipid antibodies, may accompany pernio, but their clinical importance is often unclear; occasionally, associated rheumatologic and hematologic conditions occur. 3 A related but distinct condition is chilblain lupus, a subtype of chronic cutaneous lupus erythematosus in acral locations, which is also induced by cold exposure; however, lupus-specific findings may be found on routine skin histopathology or direct immunofluorescence. 4 Chilblain lupus should not be confused with lupus pernio, which is sarcoidosis that clinically resembles pernio when it occurs on the acral surfaces of the nose, cheeks, and ears. 5 All pernio-like eruptions do not necessarily equate to a (cryoglobulins, cryofibrinogens, cold agglutinins) have been described in childhood pernio. 24 Additionally, cryofibrinogenemia has been found in TREX1-related disease 25 and chilblains during the COVID-19 pandemic, 26 pointing to cryofibrinogens as an acutephase reactant due to the IFN-I response. The association of COVID-19 and chilblainlike lesions raises the question as to why SARS-CoV-2 may trigger a lymphocytic inflammatory response at acral sites; the answer may provide additional insights into the pathogenesis of pernio.

An international dermatology registry was created to assist in documenting the dermatologic manifestations associated with COVID-19. 27 Of 505 patients with cutaneous eruptions, 318 (63%) were reported as having pernio-like eruptions, of which 94% involved the feet, 98% received outpatient care only, 55% were asymptomatic, and 45% had respiratory COVID-19 symptoms (mostly mild). 27 However, 6 patients were hospitalized, including 2 who died. Seven patients had dermatopathology, all reporting features consistent with pernio. The median age of patients was 25 years, and 29% lived where the average monthly temperature was above 10 °C. Most patients (72%) had a suspected diagnosis of COVID-19 but lacked confirmatory testing owing to access limitations; only 23 (7%) had positive results for SARS-CoV-2 polymerase chain reaction (PCR) or antibody/assay testing (46 PCR negative; 14 antibody negative).

Despite these findings, the authors concluded that the large number of reported cases of pernio during the COVID-19 pandemic was probably not merely coincidental and questioned the sensitivity of the available testing methods in patients with mild or asymptomatic disease. However, the authors conceded that even with this large case series they could not establish causation or exclude an epiphenomenon. 27 Compared to other cutaneous eruptions, pernio had a longer course of skin lesions but fewer and less severe COVID-19 symptoms, which is contrasted with the 11 patients (6.4%) with retiform purpura who all required hospitalization and respiratory support. 28 In a subgroup of COVID-19-associated pernio patients with information on the timing of SARS-CoV-2 testing, PCR positivity occurred at a median of 8 days, PCR negativity at a median of 14 days, and antibody positivity at a median of 27 days after onset of pernio. 29

It is unusual that the majority of reported cases of COVID-19-associated pernio have occurred in younger patients with no prior history of pernio and in warmer weather conditions than is typical of cold-induced pernio, pointing to COVID-19 as the most likely cause. 30 One hypothesis is that an adequate early IFN-I response to COVID-19 occurs in younger patients, 10 possibly explaining why SARS-CoV-2 PCR results are frequently negative when patients present with chilblains. 30 For example, of 22 children and adolescents presenting with chilblains to an emergency department in Spain, only 1 of the 19 tested had positive SARS-CoV-2 PCR results. 30 Additionally, an Italian group initially reported chilblain-like lesions in 4 patients 31 and subsequently reported 45 more patients with similar acral lesions 32 ; all patients tested negative with SARS-CoV-2 PCR, and only 1 of 8 tested had immunoglobulin (Ig)G antibodies to SARS-CoV-2 spike protein 1 (S1) and spike protein 2 (S2). 32 A Spanish group questioned the association of pernio with COVID-19 because 38 of 39 tested patients presenting with acral skin lesions had negative SARS-CoV-2 PCR results, 33 and an Italian group concluded that 8 pediatric patients had primary chilblains related to cold exposure during the lockdown because none had viral respiratory symptoms, known COVID-19 contacts, or detectable SARS-CoV-2 by PCR or antibody testing. 34 In another Italian series of 19 patients with histologically confirmed chilblains, 6 patients had IgA antibodies and 1 patient had IgG antibodies to SARS-CoV-in all patients. 11 A French group also reported that IgA antibodies to SARS-CoV-2 were more frequent in 40 patients presenting with chilblains, which were found in 8 of 12 patients who were antibody positive, even though PCR results were negative in 26 of 26 patients. 35 The frequently negative SARS-CoV-2 testing results raise the question of the sensitivity of the available COVID-19 tests, particularly for patients with strong innate immunity that may not lead to a measurable humoral immune response, such as younger patients who more frequently present with pernio. 36, 37 In a population-based study in Switzerland, children (5-9 years old) had the lowest seroprevalence of SARS-CoV-2 (0.8%), even though 17.1% had at least 1 seropositive household member. 38 Additionally, symptom severity is likely correlated with the degree of antibody response. For example, a study reported higher antibody titers to SARS-CoV-2 in the severe COVID-19 group compared to the nonsevere group, with a significant difference in IgG titers 2 weeks after symptom onset. 39 In this same study, among 164 close contacts of patients with known COVID-19, virus-specific IgG and/or IgM were positive in 23 (14%) approximately 30 days after exposure (10 were asymptomatic); 16 (10%) also had positive PCR results (3 were asymptomatic). 39 In another study including 37 asymptomatic patients, 30 (81%) had virus-specific IgG antibodies, although they had lower antibody levels than Another factor may be preexisting cross-reactive coronavirus antibodies that can target SARS-CoV-2, which have been found in uninfected individuals and are more prevalent at younger ages. 48 Cross-reactive immune protection was also suggested in hospitalized COVID-19 patients with previously detected endemic coronavirus, since they showed lower odds of intensive care unit admission and higher survival probability. 49 from classic viral exanthems in being defined by clinically recognizable morphology with multiple potential etiologies, which is persistent or delayed owing to the immune reaction rather than specific viral cytopathic effect .

Angiotensin-converting enzyme (ACE) 2 (ACE2) functions as the receptor on cells that mediate cellular entry for both SARS-CoV and SARS-CoV-2. 64, 65 First the viral protein subunit S1 binds to the receptor ACE2; the second step is protein cleavage of the S1 and S2 protein subunits, which is completed by the transmembrane protease serine 2 (TMPRSS2). 66, 67 After the S1 protein subunit separation, the remaining S2 protein subunit conformationally rearranges, which allows the fusion of the viral and cellular membranes and subsequent cellular entry of the virus. 66, 67 This process leads to downregulation of ACE2 on cells because it is functionally removed from the external membrane site. 67 ACE2 is primarily membrane bound on cells, although it is also detectable in lower quantities as a circulating soluble form. 67 A disintegrin and metalloproteinase 17 (ADAM17) also cleaves membrane-bound ACE2, releasing an active form into the circulation and leaving an inactive portion on the cell membrane. 67, 68 TMPRSS2 competes with ADAM17 for ACE2 processing but cleaves ACE2 differently, so that only TMPRSS2 facilitates SARS-CoV cell entry. 65, 69 

Although cell-bound ACE2 allows cellular entry for SARS-CoV-2, ACE2 also provides a vasoprotective function by converting angiotensin (ANG) II (ANGII) to ANG-(1-7) (ANG1-7). 67 Increased levels of ANGII lead to endothelial dysfunction by binding the ANG type 1 receptor (AT1R) and resulting in increased aldosterone release, vasoconstriction, coagulation, immune cell activation, and inflammatory cytokines. 67 These effects are opposed by ANG1-7 binding the ANG type 2 receptor (AT2R) and the Mas receptor, which promotes healthy endothelial function through increased levels of nitric oxide (NO), vasodilation, and an antithrombotic and anti-inflammatory state. 67

These downstream positive effects of ACE2 in balancing the renin-angiotensinaldosterone system (RAAS) lead to the paradox that despite being the viral receptor, ACE2 likely has vasoprotective effects.

Severe COVID-19 occurs more frequently in male patients 73, 74 and older patients. 75 Differences in the RAAS may be one explanation, as in males and older adults the ACE-driven ANGII-AT1R axis is favored, 76, 77 whereas in females the balance is The TLR7 gene is present on the X chromosome and escapes X chromosome inactivation, resulting in biallelic expression in a proportion of female immune cells and an increased IFN-I response. 88 In a cohort of COVID-19 patients, higher IFNα2 levels were found in females than in males; female patients (but not male patients) also showed higher IFNα2 levels than sex-matched health care worker controls. 89 

COVID-19 has been associated with several coagulation defects, including elevated D-dimer levels, pulmonary thrombosis, venous thromboembolism, and disseminated intravascular coagulation. 118 In a prospective cohort study, patients with acute respiratory distress syndrome due to COVID-19 had increased thrombotic complications, including pulmonary embolism, despite anticoagulation. 119 

Hypoxia in COVID-19 is not surprising given patients' related pneumonia with ground-glass opacities on radiologic imaging studies, although some have hypothesized that hemoglobin dysfunction may also be involved. 129 

COVID-19-associated pernio may more commonly affect younger patients because of age-related differences in cutaneous endothelial function. The complete RAAS system resides in human skin and includes ANGII, which can be synthesized locally, and its receptors AT1R and AT2R, which are found in epidermal keratinocytes and dermal vessels. 132 Cutaneous vascular responses to ANGII are age-related. 77, 133 In young adults, reflex cutaneous vasoconstriction to cold exposure is primarily dependent on sympathetic nerve activity. 134 However, thermoregulatory reflex cutaneous vasoconstriction attenuates with older age because of impaired skin sympathetic nerve activity. 135 The result in older adults is increased reliance on ANGII-mediated vasoconstriction through AT1R stimulation of the compromised sympathetic pathways. 77

The age-related differences in ANGII response also suggest that as adults age, AT1R density increases while AT2R density decreases, and the dose-response curve shifts in older adults, with less AT2R-mediated vasodilation (which is protective) at lower ANGII concentrations and more AT1R-mediated vasoconstriction (which is pathogenic) with increasing ANGII concentrations. 77 Nevertheless, younger adults do have AT1Rmediated vasoconstriction at higher levels of ANGII, but, unlike older individuals, younger adults maintain adequate reflex cutaneous vasoconstriction to cold exposure. 77, 133 Therefore, locally increased ANGII due to ACE2 deficiency from SARS-CoV-2 infection, in combination with an intact thermoregulatory vasoconstriction response, may contribute to the acral vasopasm of pernio more commonly affecting younger COVID-19 patients.

On the basis of a review of the published literature, we speculate that the mechanism for COVID-19-associated pernio (COVID toes) involves an interplay of SARS-CoV-2 cell infection through ACE2, the RAAS, sex hormones, and the IFN-I immune response (Figure 3 64-69, 76, 81, 82, 86, 87, 94, 97, 123-126, 128, 130, 136 ) . These interconnected mechanisms provide a rationale for some of the therapeutics studied in the context of COVID-19 infection, including RAAS inhibitors, recombinant ACE2, NO-mediated vasodilators, antiandrogens, antithrombotics, anti-inflammatory agents, JAK inhibitors, IL-6 antagonists, and antiviral IFNs.

IFN-Is are antiviral, by preventing viral replication, and they upregulate ACE2 epithelial expression, 110 thereby preventing ACE2 deficiency. Therefore, with robust IFN-I release in mild COVID-19, any ACE2 deficiency and subsequent increase in ANGII activity is limited, possibly triggering temporary acral vasospasm and manifesting as pernio. However, with a lessened IFN-I response, ACE2 deficiency/ANGII increase may be more pronounced, including the related endothelial dysfunction, potentially resulting in fluctuating arteriolar vasospasm (presenting as livedo reticularis 137 ) in J o u r n a l P r e -p r o o f moderate COVID-19 or protracted vasospasm and thrombosis (presenting as livedo racemosa, retiform purpura, or acral necrosis in acro-ischemia 17-19, 120 ) in severe COVID-19. The greater the degree of innate IFN-I response, the more likely that SARS-CoV-2 PCR and antibody testing will be negative; therefore, skin biopsy immunohistochemistry and blood testing for viral signature markers, including IFN-I-inducible MxA, 138 and lymphocyte assays for SARS-CoV-2-reactive T cells 139 deserve further investigation in patients with suspected COVID-19-associated pernio.

The caveats of this review include the retrospective nature of the majority of published studies; the lack of prospective data thus far is due to the novel nature of the current SARS-CoV-2 pandemic. For example, SARS-CoV-2 testing methods and results have been highly variable, as the best practices for proving infection in patients with possible cutaneous manifestations have yet to be determined. We also acknowledge that, from a review of the published literature, we have made speculative hypotheses about the potential cutaneous and systemic mechanisms involved in the pathophysiology of COVID-19-associated pernio that will need to be confirmed in future prospective studies.

Pernio or chilblains is the most common diagnosis to explain COVID toes, because affected patients present with erythema and swelling involving acral surfaces and consistent lymphocyte-rich histopathology, fulfilling the previously proposed diagnostic criteria. 3 However, it is critical to distinguish pernio from other cutaneous acral eruptions that can also be associated with COVID-19, particularly a pauci-inflammatory thromboocclusive vasculopathy, which presents with livedoid to retiform purpura or necrotic to ulcerated acral skin lesions. Therefore, it is essential to recognize any dermatologic findings potentially associated with SARS-CoV-2 infection, which are important cutaneous signs of COVID-19 severity.

J o u r n a l P r e -p r o o f Step 1: The cellular receptor ACE2 is critically important in SARS-CoV-2 infection. 64, 65 In addition, transmembrane protease serine 2 (TMPRSS2) is essential because by cleaving cell-bound ACE2 and SARS-CoV-2 spike protein subunit 1 (S1) from spike protein subunit 2 (S2), it facilitates viral cellular entry. 65, 66, 69

Step 2: Androgens and estrogens have generally opposing downstream effects on ACE2 processing, providing an explanation for more severe coronavirus disease 2019 (COVID-19) in males. TMPRSS2 activity increases with androgen sensitization through dihydrotestosterone activation of the androgen receptor (AR). 82 On the contrary, estrogens increase the expression of a disintegrin and metalloproteinase 17 J o u r n a l P r e -p r o o f (ADAM17), 81 which competes for processing of ACE2 and releases a circulating form of active ACE2. 68, 69 Therefore, increased ADAM17 activity may be protective in females, resulting in an increased proportion of circulating ACE2 that binds any circulating SARS-CoV-2 and prevents further cell infection.

Step 3: When cells are infected by SARS-CoV-2, the resulting virus-receptor internalization results in decreased cell expression of ACE2 and a relative deficiency of ACE2. 67 In the RAAS, a delicate balance exists between ACE and ACE2. ACE converts angiotensin (ANG) I (ANG I) to ANG II and, with aminopeptidase, to ANG III, both of which contribute to endothelial dysfunction through binding the angiotensin type 1 receptor (AT1R). 136 On the contrary, ACE2 converts ANG I to ANG (1-9) and ANG II to ANG (1-7), both of which promote healthy endothelial function through binding the AT2R. 136 At baseline, because of sex hormone differences, the ACE-ANG II-AT1R pathway is favored in males, whereas the ACE2-ANG 1-7-AT2R pathway is favored in females. 76

Step 4: These RAAS predilections may account for increased endothelial dysfunction in males compared to females; AT1R stimulation decreases nitric oxide (NO), is vasoconstricting, prothrombotic, and proinflammatory; AT2R stimulation increases NO, is vasodilatory, antithrombotic, and anti-inflammatory. 136 ANG II-AT1R activation also potentiates endothelial dysfunction by stimulating aldosterone synthesis and subsequent mineralocorticoid receptor activation, with similar vasculopathic and proinflammatory effects. 126

Step 5: Aldosterone stimulates mineralocorticoid receptors on dendritic cells, and ANG II stimulates AT1Rs on T cells and on dendritic cells; all these actions promote T-cell activation and proliferation. 123 This leads to activation of interleukin-6 family (IL- 

Florida COVID-19 response